The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Prostatectomy


Psychiatry related information on Prostatectomy


High impact information on Prostatectomy

  • With contemporary radical prostatectomy, about 70% of men with clinically localized disease will be cured, depending on tumor grade, tumor stage, and the serum PSA level [7].
  • Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study [8].
  • Patients were considered to have had additional cancer therapy if they had had radiation therapy, orchiectomy, and/or androgen-deprivation therapy by injection after radical prostatectomy [9].
  • BACKGROUND: Urinary incontinence is a common long-term complication after radical prostatectomy [10].
  • The value of adding chlorhexidine to urine drainage bags of male patients treated with indwelling catheters after prostatectomy and other transurethral operations was assessed in a randomised, prospective, controlled was assessed in a randomised, prospective, controlled study [11].

Chemical compound and disease context of Prostatectomy


Biological context of Prostatectomy

  • Even in the presence of allelic loss, NKX3.1 expression is reduced over a wide range in prostate cancer at the time of prostatectomy, suggesting that diverse factors influence expression [17].
  • Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy [18].
  • However, more recent data indicate that (post-treatment) PSA and PSA kinetics can be used to predict the outcome of a variety of therapeutic interventions including radical prostatectomy, radiation therapy, androgen deprivation, and treatment of hormone-refractory prostate cancer [19].
  • We determined the DNA ploidy value of each individual focus of cancer in radical prostatectomy specimens using nuclear image analysis (CAS 200 system) [20].
  • METHODS: Radical prostatectomy specimens obtained from 28 patients with PCA were analyzed by histologic and immunohistochemical methods by using 34 beta E12 and Ki-67 as primary antibodies [21].

Anatomical context of Prostatectomy


Associations of Prostatectomy with chemical compounds


Gene context of Prostatectomy


Analytical, diagnostic and therapeutic context of Prostatectomy


  1. Management of prostate cancer after prostatectomy: treating the patient, not the PSA. Scher, H.I. JAMA (1999) [Pubmed]
  2. Intravenous pyelography: the case against its routine use. Mushlin, A.I., Thornbury, J.R. Ann. Intern. Med. (1989) [Pubmed]
  3. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. Dotan, Z.A., Bianco, F.J., Rabbani, F., Eastham, J.A., Fearn, P., Scher, H.I., Kelly, K.W., Chen, H.N., Schöder, H., Hricak, H., Scardino, P.T., Kattan, M.W. J. Clin. Oncol. (2005) [Pubmed]
  4. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Shariat, S.F., Kattan, M.W., Traxel, E., Andrews, B., Zhu, K., Wheeler, T.M., Slawin, K.M. Clin. Cancer Res. (2004) [Pubmed]
  5. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Halvorsen, O.J., Haukaas, S.A., Akslen, L.A. Clin. Cancer Res. (2003) [Pubmed]
  6. Sildenafil citrate after radical retropubic prostatectomy. Lowentritt, B.H., Scardino, P.T., Miles, B.J., Orejuela, F.J., Schatte, E.C., Slawin, K.M., Elliott, S.P., Kim, E.D. J. Urol. (1999) [Pubmed]
  7. Contemporary results of anatomic radical prostatectomy. Catalona, W.J., Ramos, C.G., Carvalhal, G.F. CA: a cancer journal for clinicians. (1999) [Pubmed]
  8. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. Stanford, J.L., Feng, Z., Hamilton, A.S., Gilliland, F.D., Stephenson, R.A., Eley, J.W., Albertsen, P.C., Harlan, L.C., Potosky, A.L. JAMA (2000) [Pubmed]
  9. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. Lu-Yao, G.L., Potosky, A.L., Albertsen, P.C., Wasson, J.H., Barry, M.J., Wennberg, J.E. J. Natl. Cancer Inst. (1996) [Pubmed]
  10. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. Van Kampen, M., De Weerdt, W., Van Poppel, H., De Ridder, D., Feys, H., Baert, L. Lancet (2000) [Pubmed]
  11. Does the addition of disinfectant to urine drainage bags prevent infection in catheterised patients? Gillespie, W.A., Simpson, R.A., Jones, J.E., Nashef, L., Teasdale, C., Speller, D.C. Lancet (1983) [Pubmed]
  12. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Blank, K., Broderick, G.A., Tomaszewski, J.E., Renshaw, A.A., Kaplan, I., Beard, C.J., Wein, A. JAMA (1998) [Pubmed]
  13. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. Thomas, C.T., Bradshaw, P.T., Pollock, B.H., Montie, J.E., Taylor, J.M., Thames, H.D., McLaughlin, P.W., DeBiose, D.A., Hussey, D.H., Wahl, R.L. J. Clin. Oncol. (2003) [Pubmed]
  14. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Pruthi, R.S., Derksen, J.E., Moore, D., Carson, C.C., Grigson, G., Watkins, C., Wallen, E. Clin. Cancer Res. (2006) [Pubmed]
  15. Vardenafil: a review of its use in erectile dysfunction. Keating, G.M., Scott, L.J. Drugs (2003) [Pubmed]
  16. Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. Mirowitz, S.A., Brown, J.J., Heiken, J.P. Radiology. (1993) [Pubmed]
  17. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Asatiani, E., Huang, W.X., Wang, A., Rodriguez Ortner, E., Cavalli, L.R., Haddad, B.R., Gelmann, E.P. Cancer Res. (2005) [Pubmed]
  18. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Bastian, P.J., Palapattu, G.S., Lin, X., Yegnasubramanian, S., Mangold, L.A., Trock, B., Eisenberger, M.A., Partin, A.W., Nelson, W.G. Clin. Cancer Res. (2005) [Pubmed]
  19. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Small, E.J., Roach, M. Semin. Oncol. (2002) [Pubmed]
  20. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. Greene, D.R., Rogers, E., Wessels, E.C., Wheeler, T.M., Taylor, S.R., Santucci, R.A., Thompson, T.C., Scardino, P.T. J. Urol. (1994) [Pubmed]
  21. Postatrophic hyperplasia of the prostate in Japan: histologic and immunohistochemical features and p53 gene mutation analysis. Tsujimoto, Y., Takayama, H., Nonomura, N., Okuyama, A., Aozasa, K. Prostate (2002) [Pubmed]
  22. Telomerase activity: a prevalent marker of malignant human prostate tissue. Sommerfeld, H.J., Meeker, A.K., Piatyszek, M.A., Bova, G.S., Shay, J.W., Coffey, D.S. Cancer Res. (1996) [Pubmed]
  23. Parameters for treatment decisions for salvage radiation therapy. Hayes, S.B., Pollack, A. J. Clin. Oncol. (2005) [Pubmed]
  24. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. Wood, D.P., Banerjee, M. J. Clin. Oncol. (1997) [Pubmed]
  25. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Mohler, J.L., Chen, Y., Hamil, K., Hall, S.H., Cidlowski, J.A., Wilson, E.M., French, F.S., Sar, M. Clin. Cancer Res. (1996) [Pubmed]
  26. Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy. Martin, C., Viviand, X., Cottin, A., Savelli, V., Brousse, C., Ragni, E., Richaud, C., Mallet, M.N. Antimicrob. Agents Chemother. (1996) [Pubmed]
  27. Trimethoprim resistance in urinary isolates of coagulase-negative staphylococci in patients undergoing prostatectomy. Williams, M. Lancet (1980) [Pubmed]
  28. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Ayala, G., Wang, D., Wulf, G., Frolov, A., Li, R., Sowadski, J., Wheeler, T.M., Lu, K.P., Bao, L. Cancer Res. (2003) [Pubmed]
  29. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. Pettaway, C.A., Pisters, L.L., Troncoso, P., Slaton, J., Finn, L., Kamoi, K., Logothetis, C.J. J. Clin. Oncol. (2000) [Pubmed]
  30. Achieving optimal outcomes after radical prostatectomy. Saranchuk, J.W., Kattan, M.W., Elkin, E., Touijer, A.K., Scardino, P.T., Eastham, J.A. J. Clin. Oncol. (2005) [Pubmed]
  31. Androgens in patients with benign prostatic hyperplasia before and after prostatectomy. Vermeulen, A., De Sy, W. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  32. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Slawin, K.M., Shariat, S.F., Nguyen, C., Leventis, A.K., Song, W., Kattan, M.W., Young, C.Y., Tindall, D.J., Wheeler, T.M. Cancer Res. (2000) [Pubmed]
  33. The role of metastasis-associated protein 1 in prostate cancer progression. Hofer, M.D., Kuefer, R., Varambally, S., Li, H., Ma, J., Shapiro, G.I., Gschwend, J.E., Hautmann, R.E., Sanda, M.G., Giehl, K., Menke, A., Chinnaiyan, A.M., Rubin, M.A. Cancer Res. (2004) [Pubmed]
  34. A prostate-specific antigen-like protein associated with renal cell carcinoma in women. Clements, J., Ward, G., Kaushal, A., Hi, S.I., Kennett, C., Nicol, D. Clin. Cancer Res. (1997) [Pubmed]
  35. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Kuniyasu, H., Troncoso, P., Johnston, D., Bucana, C.D., Tahara, E., Fidler, I.J., Pettaway, C.A. Clin. Cancer Res. (2000) [Pubmed]
  36. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Di Lorenzo, G., Tortora, G., D'Armiento, F.P., De Rosa, G., Staibano, S., Autorino, R., D'Armiento, M., De Laurentiis, M., De Placido, S., Catalano, G., Bianco, A.R., Ciardiello, F. Clin. Cancer Res. (2002) [Pubmed]
  37. Re: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. Dalkin, B.L. J. Natl. Cancer Inst. (2001) [Pubmed]
  38. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. Shariat, S.F., Lamb, D.J., Kattan, M.W., Nguyen, C., Kim, J., Beck, J., Wheeler, T.M., Slawin, K.M. J. Clin. Oncol. (2002) [Pubmed]
  39. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Tsihlias, J., Kapusta, L.R., DeBoer, G., Morava-Protzner, I., Zbieranowski, I., Bhattacharya, N., Catzavelos, G.C., Klotz, L.H., Slingerland, J.M. Cancer Res. (1998) [Pubmed]
  40. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Kiyama, S., Morrison, K., Zellweger, T., Akbari, M., Cox, M., Yu, D., Miyake, H., Gleave, M.E. Cancer Res. (2003) [Pubmed]
  41. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. Wu, Y.Q., Chen, H., Rubin, M.A., Wojno, K.J., Cooney, K.A. Cancer Res. (2001) [Pubmed]
WikiGenes - Universities